OTCMKTS:NRIFF

Nuvo Pharmaceuticals Stock Forecast, Price & News

$0.97
0.00 (0.00 %)
(As of 08/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.97
▼
$0.97
50-Day Range
$0.79
▼
$1.24
52-Week Range
$0.30
▼
$0.87
VolumeN/A
Average Volume7,337 shs
Market Capitalization$11.05 million
P/E Ratio24.24
Dividend YieldN/A
Beta1.57
30 days | 90 days | 365 days | Advanced Chart
Receive NRIFF News and Ratings via Email

Sign-up to receive the latest news and ratings for Nuvo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


About Nuvo Pharmaceuticals

Nuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. Nuvo Pharmaceuticals was founded on August 22, 1983 and is headquartered in Mississauga, Canada.

Headlines

Miravo HealthcareTM Ireland Enters into Suvexx® License and Supply Agreement with SK Chemicals Co., Ltd. for South Korea
Miravo HealthcareTM Ireland Enters into Suvexx® License and Supply Agreement with SK Chemicals Co., Ltd. for South Korea
July 29, 2021 |  benzinga.com
Nuvo Pharmaceuticals® Announces Corporate Rebranding as Miravo Healthcare™
Nuvo Pharmaceuticals® Announces Corporate Rebranding as Miravo Healthcare™
December 18, 2020 |  finance.yahoo.com
Nuvo Pharmaceuticals Inc (NRIFF) CEO Jesse Ledger on Q3 2020 Results - Earnings Call Transcript
Nuvo Pharmaceuticals Inc (NRIFF) CEO Jesse Ledger on Q3 2020 Results - Earnings Call Transcript
November 17, 2020 |  seekingalpha.com
Nuvo Pharmaceuticals Inc. 2020 Q3 - Results - Earnings Call Presentation
Nuvo Pharmaceuticals Inc. 2020 Q3 - Results - Earnings Call Presentation
November 16, 2020 |  seekingalpha.com
FP Markets recognised as Best FX Broker Australia for 2020
FP Markets recognised as 'Best FX Broker Australia' for 2020
November 5, 2020 |  finance.yahoo.com
How Much Is Nuvo Pharmaceuticals' (TSE:NRI) CEO Getting Paid?
How Much Is Nuvo Pharmaceuticals' (TSE:NRI) CEO Getting Paid?
November 3, 2020 |  finance.yahoo.com
Nuvo Pharmaceuticals® to Webcast Live at Life Sciences Investor Forum September 17th
Nuvo Pharmaceuticals® to Webcast Live at Life Sciences Investor Forum September 17th
September 14, 2020 |  finance.yahoo.com
Nuvo Pharmaceuticals Inc. 2020 Q2 - Results - Earnings Call Presentation
Nuvo Pharmaceuticals Inc. 2020 Q2 - Results - Earnings Call Presentation
August 10, 2020 |  seekingalpha.com
Nuvo Pharmaceuticals Inc (NRIFF) CEO Jesse Ledger on Q2 2020 Results - Earnings Call Transcript
Nuvo Pharmaceuticals Inc (NRIFF) CEO Jesse Ledger on Q2 2020 Results - Earnings Call Transcript
August 10, 2020 |  seekingalpha.com
Nuvo Research Inc (NRIFF)
Nuvo Research Inc (NRIFF)
August 2, 2020 |  www.nasdaq.com
See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank™

Overall MarketRank™

1.10 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Nuvo Pharmaceuticals (OTCMKTS:NRIFF) Frequently Asked Questions

What stocks does MarketBeat like better than Nuvo Pharmaceuticals?

Wall Street analysts have given Nuvo Pharmaceuticals a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Nuvo Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How has Nuvo Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Nuvo Pharmaceuticals' stock was trading at $0.6007 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NRIFF shares have increased by 61.4% and is now trading at $0.9697.
View which stocks have been most impacted by COVID-19.

Who are Nuvo Pharmaceuticals' key executives?

Nuvo Pharmaceuticals' management team includes the following people:
  • Jesse Ledger, President & Chief Executive Officer
  • Kelly Demerino, Chief Financial Officer
  • Bernard Chiasson, Chief Scientific Officer
  • Wade Hull, Vice President-Research & Development
  • Katina K. Loucaides, Secretary, Vice President & General Counsel

Who are some of Nuvo Pharmaceuticals' key competitors?

Some companies that are related to Nuvo Pharmaceuticals include CNS Pharmaceuticals (CNSP), Antibe Therapeutics (ATBPF), Trevi Therapeutics (TRVI), Addex Therapeutics (ADDXF), Appili Therapeutics (APLIF), Emerald Bioscience (EMBI), Soligenix (SNGX), China Pharma (CPHI), TransCode Therapeutics (RNAZ), CURE Pharmaceutical (CURR), RegeneRx Biopharmaceuticals (RGRX), Ceapro (CRPOF), Unicycive Therapeutics (UNCY), Bellerophon Therapeutics (BLPH) and Timber Pharmaceuticals (TMBR).
View all of NRIFF's competitors.

What is Nuvo Pharmaceuticals' stock symbol?

Nuvo Pharmaceuticals trades on the OTCMKTS under the ticker symbol "NRIFF."

How do I buy shares of Nuvo Pharmaceuticals?

Shares of NRIFF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nuvo Pharmaceuticals' stock price today?

One share of NRIFF stock can currently be purchased for approximately $0.97.

How much money does Nuvo Pharmaceuticals make?

Nuvo Pharmaceuticals has a market capitalization of $11.05 million and generates $52.41 million in revenue each year.

How many employees does Nuvo Pharmaceuticals have?

Nuvo Pharmaceuticals employs 99 workers across the globe.

What is Nuvo Pharmaceuticals' official website?

The official website for Nuvo Pharmaceuticals is www.nuvopharmaceuticals.com.

Where are Nuvo Pharmaceuticals' headquarters?

Nuvo Pharmaceuticals is headquartered at 6733 MISSISSAUGA ROAD SUITE 610, MISSISSAUGA A6, L5N 6J5.

How can I contact Nuvo Pharmaceuticals?

Nuvo Pharmaceuticals' mailing address is 6733 MISSISSAUGA ROAD SUITE 610, MISSISSAUGA A6, L5N 6J5. The company can be reached via phone at (905) 673-6980 or via email at [email protected]


This page was last updated on 8/5/2021 by MarketBeat.com Staff

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.